Latest results on Oncofid®P-B, at the American Urological Association’s 2019 Annual Meeting

Fidia farmaceutici today announced the positive preliminary results from an open-label, single-arm, multicenter clinical trial evaluating safety, tolerability and efficacy of Oncofid®P-B, an innovative Paclitaxel-Hyaluronic Acid conjugate, in patients with carcinoma in situ (CIS) of the bladder, unresponsive or intolerant to BCG (Bacillus Calmette-Guérin) and unwilling or unfit for cystectomy.

Dr. Rodolfo Hurle, Principal Investigator at Humanitas Research Hospital in Milan (Italy) was invited as a podium speaker on Friday, May 3 at 4:00 PM (Chicago Local Time) and explained the results and conclusions of the trial.

Good efficacy and excellent tolerability

Oncofid®P-B showed excellent tolerability for a prolonged treatment schedule and good efficacy, with 72.2% complete response in patients who completed the 12-week induction phase, followed by 12 monthly instillations (maintenance),

A pharmacological alternative to cystectomy

CIS of the bladder is still an unmet medical need and the excellent safety profile and positive preliminary efficacy results obtained with Oncofid®P-B when administered according to a prolonged treatment schedule support the further clinical development of this innovative drug - said Dr. Hurle – providing a potential pharmacological alternative to cystectomy for these high-risk patients”.


Find out more about Fidia’s product portfolio:

Go to the website

Key Business Areas

Fidia operates in numerous therapeutic areas, providing specific, innovative treatments for commonly occurring pathologies with major socio-economic impact, namely:

- joint care
- ophthalmology
- active wound care
- neuroscience
- aesthetic medicine